The bone marrow has emerged as a potentially important target in cardiovascular disease as it generates all leukocytes involved in atherogenesis. In the current study, we evaluated whether a change in bone marrow functionality underlies the increased atherosclerosis susceptibility associated with high-density lipoprotein (HDL) deficiency. We found that HDL deficiency in mice due to the genetic lack of hepatocyte-derived apolipoprotein A1 (APOA1) was associated with an increase in the Lin−Sca-1+Kit+ (LSK) bone marrow stem cell population and lymphoid-primed multipotent progenitor numbers, which translated into a higher production and systemic flux of T cell subsets. In accordance with APOA1 deficiency-associated priming of stem cells to increase T lymphocyte production, atherogenic diet-fed low-density lipoprotein receptor knockout mice transplanted with bone marrow from APOA1-knockout mice displayed marked lymphocytosis as compared to wild-type bone marrow recipients. However, atherosclerotic lesion sizes and collagen contents were similar in the two groups of bone marrow recipients. In conclusion, systemic lack of APOA1 primes bone marrow stem cells for T cell lymphopoiesis. Our data provide novel evidence for a regulatory role of HDL in bone marrow functioning in normolipidemic mice.
Fasting alters insulin secretion in humans and islet cell composition in mice. Fasting triggers ketogenesis, which increases beta hydroxybutyrate (BHB) levels. BHB is a signaling molecule that alters insulin secretion in primary islets. We hypothesized that BHB alters human islet cell composition and identity. Primary human islets were cultured with R-BHB or its non-metabolizable enantiomer, S-BHB. Human islets cultured with R-BHB, but not S-BHB, resulted in an increased C-peptide-glucagon+ to C-peptide+glucagon- cell ratio, and an increased frequency of C-peptide+glucagon+ bihormonal cells and NKX6.1+glucagon+ cells. Single-cell transcriptomics revealed upregulation of alpha cell identity genes in R-BHB treated islet beta cells. Alterations in beta cell identity were accompanied by increased basal insulin secretion in response to low glucose, and a reduced insulin stimulation index in response to high glucose. The differential effects of the two BHB enantiomers on islet cell composition indicated that ketone metabolism is involved in islet cell identity change. Supporting this hypothesis, a subpopulation of beta cells in islets treated with R-BHB characterized by low ketolysis genes, OXCT1 and ACAT1, did not show altered alpha and beta cell identity genes. Additionally, primary islets from type 2 diabetes donors, which exhibited reduced OXCT1 and ACAT1 expression relative to donors without diabetes, did not display altered islet cell composition and beta cell function from R-BHB treatment. Our findings uncover a novel role of BHB in modulating beta cell identity, with potential implications for islet function in states with chronically elevated ketone concentrations.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by accumulation of lipids within hepatocytes. Conflicting evidence exists regarding the role of protein arginine methyltransferase 1 (PRMT1) in MASLD. Here we investigated the outcome of MASLD treatment with the PRMT1 inhibitor TC-E 5003 in mice fed a Western high-fat/high cholesterol diet. Chronic exposure of male low-density lipoprotein receptor knockout mice to 10 mg/kg TC-E 5003 reduced hepatic triglyceride levels (−37%; p < 0.05) and gene expression levels of the lipogenic factors SREBP-1 (−44%; p < 0.05) and FASN (−42%; p < 0.05). In addition, TC-E 5003 lowered pro-atherogenic very-low-density and low-density lipoprotein concentrations and reduced aortic macrophage foam cell accumulation. However, chronic treatment with 10 mg/kg TC-E 5003 was also associated with unexpected toxicity and mortality. A follow-up study in female APOE*3-Leiden.CETP mice showed that chronic treatment with 2.5 mg/kg TC-E 5003 was also associated with a significant reduction in hepatic triglyceride stores (−24%; p < 0.05) in the absence of adverse effects. Radiolabeled lipoprotein flux studies uncovered a 2-fold increase (p < 0.05) in brown adipose tissue triglyceride-derived fatty-acid uptake upon TC-E 5003 treatment, although the contribution of specific PRMT1 inhibition to this effect could not be established. In conclusion, TC-E 5003 consistently reduced hepatic triglyceride accumulation in two mouse models of metabolic dysfunction-associated steatotic liver disease. While the precise contribution of PRMT1 inhibition remains to be established, the present findings demonstrate that treatment with TC-E 5003 exerts robust steatosis-lowering effects in vivo and warrant further investigation as a potential therapeutic approach for MASLD.